In 2018, Mezquita et al. firstly introduced the pre-treatment LIPI for patients with advanced NSCLC undergoing programmed death 1 (PD-1)/PD-L1 inhibitor therapy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.